Navigation Links
Spherix Announces Statistically Significant Results in Phase 3 Study With D-tagatose in Type 2 Diabetes
Date:10/7/2010

ngs:  BioPartnering Europe, October 11-12 in London; and the Windhover Therapy Area conference, November 3-4 in Boston.

TriglyceridesBecause of the small number of patients enrolled in the NEET diabetes trial with triglyceride levels of 200 to 500 mg/dl, and a lack of patients with triglyceride levels above 500 mg/dl, it was not possible to conduct statistical analyses on that secondary endpoint in the current trial.  Dr. Lodder's previous research in an animal model of dietary-induced hyperlipidemia demonstrated an effect of D-tagatose on triglycerides, VLDL, LDL in blood, and on atherosclerosis in arterial walls.  Animals consuming Dtagatose exhibited a statistically significant five- to six-fold reduction in triglycerides compared with animals consuming sucrose.

"We plan to continue with our stated goal of investigating the development of D-tagatose as a therapy for reduction of triglycerides," Dr. Lodder said.

NEET Trial Design NEET is a double-blind, placebo-controlled trial with 356 treatment-naïve patients randomized to receive 15 grams of D-tagatose three times daily with meals for a period of up to one year as an adjunct to diet and exercise, or a placebo three times daily with meals for up to one year as an adjunct to diet and exercise.  Patients were treated for more than 10 months, and HbA1c levels were measured at two, six and 10 months after enrollment into the trial.  The average HbA1c level at the time of entering the trial was 7.5%. The NEET inclusion criteria for HbA1c in patients were screening (visit 1) and randomization (visit 2) values between 6.6% and 9.0%.

A modified Intent-To-Treat (ITT) definition was used in NEET.  The modified ITT population consisted of all randomized subjects who received at least one dose of their randomized treatment and had at least one post-treatment visit evaluating efficacy.  The PP population consisted of all ITT subjects who had 80% compli
'/>"/>

SOURCE Spherix Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Spherix Announces Second Quarter 2010 Financial Results
2. Spherix Announces the Closing of $6.3 Million Registered Direct Offering
3. Spherix Announces Results of Annual Shareholders Meeting
4. Spherix Incorporated Announces Annual Shareholders Meeting Date
5. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
6. Spherix Incorporated to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
7. Spherix Reports Second Quarter 2009 Earnings
8. Spherix Announces Termination of Arla License Agreement
9. Spherix Announces Full-Scale Production of Pharmaceutical Tagatose
10. Spherix Regains Full NASDAQ Compliance
11. Spherix to Exhibit at the BIO 2009 International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015 Shire plc (LSE: SHP, ... Mathew to its Board of Directors as a Non-Executive ... Compliance & Risk Committee of the Shire Board. Both appointments ... Sara previously served as Chairman, President and Chief Executive Officer ... During her 12-year tenure at D&B, she helped drive the ...
(Date:8/31/2015)... , Aug. 31, 2015 MabVax Therapeutics ... company announces that the Company,s lead antibody, HuMab 5B1, ... five separate presentations during the upcoming World Molecular Imaging ... September 2-5, 2015. Researchers from the Department of ... present results on the use of MabVax,s lead antibody ...
(Date:8/31/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cbgl72/middle_east_and ) has ... Africa Biomedical Sensors Market - Growth, Trends & Forecasts ... The Middle East & Africa ... 2018 at a CAGR of 3.26% over the period ... sensors that are adaptable to the genetic formulation of ...
(Date:8/31/2015)... , Aug. 31, 2015  US-Australian drug discovery ... ) today confirmed its comprehensive scientific review has ... platforms in areas of unmet patient need. Novogen ... remaining preclinical projects prior to entering into Phase ... Acting Chief Executive Officer, Iain ...
Breaking Biology Technology:Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2Novogen Announces The Outcome Of A Comprehensive Science Review 2Novogen Announces The Outcome Of A Comprehensive Science Review 3Novogen Announces The Outcome Of A Comprehensive Science Review 4Novogen Announces The Outcome Of A Comprehensive Science Review 5Novogen Announces The Outcome Of A Comprehensive Science Review 6
... Health , Inc. (Nasdaq: GHDX ) today announced that ... November 8 at 4:30 p.m. Eastern Time to discuss its third ... release of the third quarter financial results after market close. ... access the live conference call on November 8 at 4:30 p.m. ...
... Verenium Corporation (Nasdaq: VRNM ), a ... solutions, today announced that it has renewed and extended ... global provider of heat transfer, separation and fluid handling ... Laval signed an agreement to jointly market enzymatic degumming ...
... the physiocrine therapeutics company, today announced a $23 ... Associates.  Domain joins existing venture investors Alta Partners, ... in the financing.  Proceeds will be used to ... advance physiocrine drug candidates into clinical trials.  Physiocrines ...
Cached Biology Technology:Genomic Health to Announce Third Quarter 2010 Financial Results and Host Conference Call on Monday, November 8, 2010 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 2Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 3Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement 4aTyr Pharma Secures $23M Financing From Top Tier Venture Investor 2
(Date:8/6/2015)... REDWOOD CITY, Calif. , Aug. 6, 2015 ... (D-Silicon Valley) will visit Crossmatch ™ to ... secure networks and protect data. Crossmatch is a ... solutions whose technologies and expertise are helping federal ... operational efficiency and security.   "The ...
(Date:8/5/2015)... , Aug. 5, 2015 The biosensors market ... in applications, penetration into newer sectors, and development of ... global biosensors space has seen the entry of multiple ... so far. (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... Analysis of the Global Biosensors Market ( ...
(Date:7/31/2015)... , 31 de julio de 2015 BGI llevará ... www.icg-10.org ) del 22 al 25 de octubre de ... La conferencia celebra su décimo aniversario este año. ... en una de las reuniones anuales más influyentes del ... una de las conferencias científicas más dinámicas, entusiastas y ...
Breaking Biology News(10 mins):Rep. Honda to Visit Crossmatch in Redwood City 2Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... the RIKEN SPring-8 Center in Harima, Japan have clarified ... (qNOR), a bacterial enzyme that offers clues on the ... their importance to fundamental science, the findings provide key ... and greenhouse gas hundreds of times more potent than ...
... 2012 /PRNewswire-iReach/ -- Global Information Inc. (GII) is ... in Medical Applications: The Global Market " by BCC ... The global nanomedicine market reached $63.8 billion ... expected to grow to $130.9 billion by 2016 at a ...
... ethanol, the type of alcohol found in alcoholic beverages, can ... known as Caenorhabditis elegans , which is used frequently ... scientists said they find their discovery difficult to explain. ... Steven Clarke, a UCLA professor of chemistry and biochemistry and ...
Cached Biology News:New study sheds light on evolutionary origin of oxygen-based cellular respiration 2Nanotechnology in Medical Applications: The Global Market 2Nanotechnology in Medical Applications: The Global Market 3Tiny amounts of alcohol dramatically extend a worm's life, but why? 2Tiny amounts of alcohol dramatically extend a worm's life, but why? 3Tiny amounts of alcohol dramatically extend a worm's life, but why? 4